Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial.
Pharmaceutics
; 14(10)2022 Sep 22.
Article
in En
| MEDLINE
| ID: mdl-36297443
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Pharmaceutics
Year:
2022
Document type:
Article
Affiliation country:
Italy
Country of publication:
Switzerland